Incretin-based investigational therapies for the treatment of MASLD/MASH

The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is estimated to be 32% among adults.

• MASLD is the most common form of chronic liver disease, existing as simple steatosis or progressive metabolic dysfunction-associated steatohepatitis (MASH).
• Simple steatosis is often considered benign and reversible, while MASH can progress to cirrhosis, liver failure, and hepatocellular carcinoma.
• Treatment strategies for MASH aim to slow, stop, or reverse the disease progression.
• Evidence suggests that therapies leading to sustained body weight reduction may improve liver tissue health.
• Incretin-based therapies, including glucagon-like peptide-1 receptor agonists and combinations with other agonists, are being investigated for their benefits in MASLD/MASH treatment.

AI simplified